A structural analysis of the differential cytotoxicity of chemicals in the NCI-60 cancer cell lines

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 7, 2008, Pages 4052-4063

  Chakravarti, Suman K ^a   Klopman, Gilles ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b MULTICASE Inc   (United States)

Author keywords

Anti cancer; Differential cytotoxicity; MULTICASE; NCI 60

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONYL DERIVATIVE; DAUNORUBICIN; NSC 155693; NSC 165677; NSC 177499; NSC 18877; NSC 352299; NSC 354462; NSC 35607; NSC 659779; NSC 665487; NSC 682298; NSC 716767; NSC 7168767; NSC 76627; NSC 80465; NSC 93134; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER GROWTH; CANCER INHIBITION; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SPECIFICITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; METHODOLOGY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; NATIONAL CANCER INSTITUTE (U.S.); UNITED STATES;

EID: 41649092024     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.01.024     Document Type: Article

References (39)

1. Grever M.R., Schepartz S.A., and Chabner B.A. Semin. Oncol. 19 (1992) 622-638
2. Boyd, Michael R. The NCI in vitro anti-cancer drug discovery screen: concept, implementation, and operation, 1985-1995; The NCI in vitro anti-cancer drug discovery screen: concept, implementation, and operation, 1985-1995, Div. Cancer Treatment, National Cancer Inst., Frederick Cancer Res. Devel. Center, Frederick, MD, USA.
3. Boyd M.R., and Paull K.D. Drug Dev. Res. 34 (1995) 91-109
4. Monks A., Scudiero D.A., Johnson G.S., Paull K.D., and Sausville E.A. Anti-cancer Drug Des. 12 (1997) 533-541
5. Stinson S.F., Alley M.C., Kopp W.C., Fiebig H.H., Mullendore L.A., Pittman A.F., Kenney S., Keller J., and Boyd M.R. Anti-cancer Res. 12 (1992) 1035-1053
6. Myers T.G., Anderson N.L., Waltham M., Li G., Buolamwini J.K., Scudiero D.A., Paull K.D., Sausville E.A., and Weinstein J.N. Electrophoresis 18 (1997) 647-653
7. Dai Z., Sadee W., and Blower P. Curr. Pharmacogenomics 5 (2006) 11-19
8. Cao X., Fang L., Gibbs S., Huang Y., Dai Z., Wen P., Zheng X., Sadee W., and Sun D. Cancer Chemother. Pharmacol. 59 (2007) 495-505
9. Szakacs G., Annereau J.P., Lababidi S., Shankavaram U., Arciello A., Bussey K.J., Reinhold W., Guo Y., Kruh G.D., Reimers M., Weinstein J.N., and Gottesman M.M. Cancer Cell 6 (2004) 129-137
10. Gottesman M.M. Annu. Rev. Med. 53 (2002) 615-627
11. Fojo T., and Bates S. Oncogene 22 (2003) 7512-7523
12. Staunton J.E., Slonim D.K., Coller H.A., Tamayo P., Angelo M.J., Park J., Scherf U., Lee J.K., Reinhold W.O., Weinstein J.N., Mesirov J.P., Lander E.S., and Golub T.R. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 10787-10792
13. Andersson C.R., Fryknaes M., Rickardson L., Larsson R., Isaksson A., and Gustafsson M.G. J. Chem. Inf. Model 47 (2007) 239-248
14. Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., Iyer V., Jeffrey S.S., Van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., and Brown P.O. Nat. Genet. 24 (2000) 227-235
15. Huang Y., Blower P.E., Yang C., Barbacioru C., Dai Z., Zhang Y., Xiao J.J., Chan K.K., and Sadee W. Pharmacogenomics J. 5 (2005) 112-125
16. Blower P.E., Yang C., Fligner M.A., Verducci J.S., Yu L., Richman S., and Weinstein J.N. Pharmacogenomics J. 2 (2002) 259-271
17. Scherf U., Ross D.T., Waltham M., Smith L.H., Lee J.K., Tanabe L., Kohn K.W., Reinhold W.C., Myers T.G., Andrews D.T., Scudiero D.A., Eisen M.B., Sausville E.A., Pommier Y., Botstein D., Brown P.O., and Weinstein J.N. Nat. Genet. 24 (2000) 236-244
18. Covell D.G., Huang R., and Wallqvist A. Mol. Cancer Ther. 6 (2007) 2261-2270
19. Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., and Yamori T. Mol. Cancer Ther. 4 (2005) 399-412
20. Rickardson L., Fryknaes M., Dhar S., Loevborg H., Gullbo J., Rydaker M., Nygren P., Gustafsson M.G., Larsson R., and Isaksson A. Br. J. Cancer 93 (2005) 483-492
21. Klopman G. Quantitative Structure-Activity Relationships 11 (1992) 176-184
22. Paull K.D., Lin C.M., Malspeis L., and Hamel E. Cancer Res. 52 (1992) 3892-3900
23. Sawicki S.G., and Godman G.C. J. Cell. Biol. 50 (1971) 746-761
24. Lampidis T.J., Shi Y.-F., Calderon C.L., Kolonias D., Tapiero H., and Savaraj N. Leukemia 11 (1997) 1156-1159
25. Hoki Y., Fujimori A., and Pommier Y. Cancer Chemother. Pharmacol. 40 (1997) 433-438
26. Freije J.M.P., Lawrence J.A., Hollingshead M.G., de la Rosa A., Narayanan V., Grever M., Sausville E.A., Paull K., and Steeg P.S. Nat. Med. (N.Y.) 3 (1997) 395-401
27. Klopman G. J. Am. Chem. Soc. 106 (1984) 7315-7321
28. Klopman G., Chakravarti S.K., Harris N., Ivanov J., and Saiakhov R.D. SAR and QSAR in Environmental Research 14 (2003) 165-180
29. Klopman G., and Chakravarti S.K. Chemosphere 51 (2003) 445-459
30. Klopman G., and Chakravarti S.K. Chemosphere 51 (2003) 461-468
31. Klopman G., and Tu M. J. Med. Chem. 42 (1999) 992-998
32. Abel U., Simon W., Eckard P., and Hansske F.G. Bioorg. Med. Chem. Lett. 16 (2006) 3292-3297
33. Cassady J.M., Byrn S.R., Stamos I.K., Evans S.M., and McKenzie A. J. Med. Chem. 21 (1978) 815-819
34. Kupchan, S. M.; Eakin, M. A.; Thomas, A. M. J Med Chem 14, 1147-1152.
35. Lee K.H., Huang E.S., Piantadosi C., Pagano J.S., and Geissman T.A. Cancer Res. 31 (1971) 1649-1654
36. Shimada H., Grutzner J.B., Kozlowski J.F., and McLaughlin J.L. Biochemistry 37 (1998) 854-866
37. Friedrich T., van Heek P., Leif H., Ohnishi T., Forche E., Kunze B., Jansen R., Trowitzsch-Kienast W., and Hoefle G. Eur. J. Biochem. 219 (1994) 691-698
38. Halmos T., Cardon A., and Antonakis K. Chem. -Biol. Interact. 46 (1983) 11-29
39. Pati H.N., Das U., Sharma R.K., and Dimmock J.R. Mini-Rev. Med. Chem. 7 (2007) 131-139